Sanofi teams with vir­tu­al re­al­i­ty biotech on oral Dupix­ent suc­ces­sor

Sanofi’s lat­est bet on a po­ten­tial Dupix­ent se­quel is a pre­clin­i­cal pill de­vel­oped by a British small-cap that spe­cial­izes in vir­tu­al re­al­i­ty chem­istry.

The French …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER